This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Patient-Physician Relationship/ Care  • Psychosocial Issues  • Psychiatry  • Depression  • Statistics and Research Methods  • Diagnosis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Drs Schulte-Herbrüggen and Röpke question whether the treatment with escitalopram may have provided some neuroprotective function through mechanisms such as neurogenesis or increase in neuropeptides that have been identified in animal models of neuropathology. We only assessed activities of daily living and cognitive function. We did not find any significant time x treatment interaction in Functional Independence Measure scores over the course of the year. We also found no significant differences in recurrent stroke or hospitalization for cardiovascular illness. It is possible, however, that longer-term follow-up may show lower differential rates of recurrence of stroke or cardiovascular morbidity or mortality.¹

Dr Dettling and colleagues question whether an item-by-item comparison of HDRS scores may have demonstrated significant effects related to hemispheric brainstem or cerebellar lesion location and their effect on depressive symptoms. We have previously tried to examine this issue of syndromic presentation of depressive disorder in patients with . . . [Full Text of this Article]

Robert G. Robinson, MD
robert-robinson@uiowa.edu

Ricardo E. Jorge, MD; Stephan Arndt, PhD
Department of Psychiatry
University of Iowa Carver College of Medicine
Iowa City

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression: A Randomized Controlled Trial
Robert G. Robinson, Ricardo E. Jorge, David J. Moser, Laura Acion, Ana Solodkin, Steven L. Small, Pasquale Fonzetti, Mark Hegel, and Stephan Arndt
JAMA. 2008;299(20):2391-2400.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Escitalopram, Problem-Solving Therapy, and Poststroke Depression
Olaf Schulte-Herbrüggen and Stefan Röpke
JAMA. 2008;300(15):1757.
EXTRACT | FULL TEXT  

Escitalopram, Problem-Solving Therapy, and Poststroke Depression
Michael Dettling, Carolin Opgen-Rhein, and Ion Anghelescu
JAMA. 2008;300(15):1757.
EXTRACT | FULL TEXT  

Escitalopram, Problem-Solving Therapy, and Poststroke Depression
Jeffrey Lacasse and Jonathan Leo
JAMA. 2008;300(15):1757-1758.
EXTRACT | FULL TEXT  

Escitalopram, Problem-Solving Therapy, and Poststroke Depression
Alice Rasmussen, Jamal A. Hanash, and Per Bech
JAMA. 2008;300(15):1758.
EXTRACT | FULL TEXT